Neovasc Inc. Ending Cash

Ending Cash of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Ending Cash growth rates and interactive chart.


Highlights and Quick Summary

  • Ending Cash for the quarter ending March 31, 2022 was $44.2 Million (a -1129.53% decrease compared to previous quarter)
  • Year-over-year quarterly Ending Cash decreased by -713.46%
  • Annual Ending Cash for 2021 was $51.5 Million (a 298.41% increase from previous year)
  • Annual Ending Cash for 2020 was $12.9 Million (a 144.41% increase from previous year)
  • Annual Ending Cash for 2019 was $5.29 Million (a -42.74% decrease from previous year)
  • Twelve month Ending Cash ending March 31, 2022 was $25.2 Million (a -51.09% decrease compared to previous quarter)
  • Twelve month trailing Ending Cash decreased by -61.09% year-over-year
Trailing Ending Cash for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$25.2 Million $51.5 Million $54.7 Million $64.8 Million
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Ending Cash of Neovasc Inc.

Most recent Ending Cashof NVCN including historical data for past 10 years.

Interactive Chart of Ending Cash of Neovasc Inc.

Neovasc Inc. Ending Cash for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $44.16
2021 $-4.29 $-7.47 $-7.2 $70.49 $51.54
2020 $-1.1 $2.59 $4.41 $7.04 $12.94
2019 $-6.1 $-6.94 $6.22 $12.12 $5.29
2018 $-5.24 $-5.59 $7.82 $12.26 $9.24
2017 $11.24 $-5.31 $-4.63 $16.21 $17.51
2016 $-2.53 $-10.8 $-10.63 $46.9 $22.95
2015 $-9.36 $-4.29 $-5.75 $74.42 $55.03
2014 $-3.48 $-5.45 $-1.25 $15.63 $5.19
2013 $-0.71 $-1.33 $0.52 $4.82 $3.3
2012 $3.83 $0.92 $0.43 $0.68 $5.86
2011 $2.4 $2.4

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.